Literature DB >> 1849447

Mixed glioblastoma multiforme and sarcoma. A clinicopathologic study of 26 radiation therapy oncology group cases.

J M Meis1, K L Martz, J S Nelson.   

Abstract

Twenty-six cases are reported of gliosarcoma (GS) retrieved from a series of 1479 glioblastomas (GBM) that were part of five consecutive, randomized Phase II or III malignant glioma protocols initiated by the Radiation Therapy Oncology Group between 1974 and 1983. The clinicopathologic features of these 26 cases, including actuarial survival times, were compared with the remaining 1453 GBM. The minimal qualitative and quantitative histologic criteria required to diagnose GS are presented. In most cases the sarcomatous component was a malignant fibrous histiocytoma; a minority were fibrosarcoma. No significant differences between GS and GBM were found with regard to age, sex, pretreatment Karnofsky performance status, tumor location, size, median survival (8.3 and 9.6 months, respectively), and actuarial survival. None of the treatment regimens, which included various combinations of radiation therapy and chemotherapy, improved the survival of GS over GBM. Selective involvement of the temporal lobe by GS was not found, and the frequency of GS was determined to be only 1.8% of all GBM.

Entities:  

Mesh:

Year:  1991        PMID: 1849447     DOI: 10.1002/1097-0142(19910501)67:9<2342::aid-cncr2820670922>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  52 in total

1.  Malignant fibrous histiocytoma presenting as an intraventricular mass five years after incidental detection of a mass lesion.

Authors:  J M Baehring; S Alemohammed; S E Croul
Journal:  J Neurooncol       Date:  2001-04       Impact factor: 4.130

2.  Dural lesions mimicking meningiomas: A pictorial essay.

Authors:  Danai Chourmouzi; Stamatia Potsi; Anestis Moumtzouoglou; Elisavet Papadopoulou; Kostas Drevelegas; Thomas Zaraboukas; Antonios Drevelegas
Journal:  World J Radiol       Date:  2012-03-28

Review 3.  Therapeutic management of gliosarcoma in the temozolomide era.

Authors:  Mary Frances McAleer; Paul D Brown
Journal:  CNS Oncol       Date:  2015-04-23

4.  Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.

Authors:  J Castelli; L Feuvret; Q C Haoming; J Biau; E Jouglar; A Berger; G Truc; F Llamas Gutierrez; X Morandi; P J Le Reste; F Thillays; D Loussouarn; E Nouhaud; G Crehange; D Antoni; E Vauleon; R de Crevoisier; G Noel
Journal:  J Neurooncol       Date:  2016-05-11       Impact factor: 4.130

5.  Cell of origin determines tumor phenotype in an oncogenic Ras/p53 knockout transgenic model of high-grade glioma.

Authors:  Sabah O Ghazi; Michelle Stark; Zhiguo Zhao; Bret C Mobley; Alex Munden; Laura Hover; Ty William Abel
Journal:  J Neuropathol Exp Neurol       Date:  2012-08       Impact factor: 3.685

6.  Multi-focal gliosarcoma: a case report and review of the literature.

Authors:  E E Pakos; A C Goussia; V P Zina; E J Pitouli; P G Tsekeris
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

7.  Gliosarcomas: analysis of 11 cases do two subtypes exist?

Authors:  Maurizio Salvati; Emanuela Caroli; Antonino Raco; Felice Giangaspero; Roberto Delfini; Luigi Ferrante
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

8.  Gliosarcoma: a study of four cases.

Authors:  Yildiz Güney; Ayse Hiçsönmez; Sercan Yilmaz; Yasemin Güzle Adas; Meltem Nalca Andrieu
Journal:  Rare Tumors       Date:  2010-06-30

9.  Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo.

Authors:  Ana C deCarvalho; Kevin Nelson; Nancy Lemke; Norman L Lehman; Ali S Arbab; Steven Kalkanis; Tom Mikkelsen
Journal:  Stem Cells       Date:  2010-02       Impact factor: 6.277

10.  Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome.

Authors:  Kevin R Kozak; Anand Mahadevan; John S Moody
Journal:  Neuro Oncol       Date:  2008-09-09       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.